News Agency
The Times

Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress

  • Written by PR Newswire

SHANGHAI, June 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, presented two latest clinical study results of its independently developed Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) in cervical cancer at the European Society...

Read more: Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological...

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion